24 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
; and
the potential impact of public health epidemics or pandemics, including the COVID-19 pandemic, and of global economic developments, including rising inflation … -19 pandemic and our response to the pandemic; and
our expectations regarding the time during which we will be an emerging growth company under
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
the COVID-19 pandemic, and of global economic developments, including rising inflation and interest rates, on our business, operations, strategy and goals … pandemic and our response to the pandemic; and
our expectations regarding the time during which we will be an emerging growth company under
S-3ASR
cua8n
23 Sep 22
Automatic shelf registration
4:08pm
424B5
tzd124abp3bx b2
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
ruhkh2l1cpi 59zhl2o
20 Jul 22
Prospectus supplement for primary offering
4:22pm
S-3
f8m7p004lu
1 Jul 22
Shelf registration
4:36pm
10-K
90ninm
14 Mar 22
Annual report
7:04am
10-Q
phfi yl80
12 Aug 21
Quarterly report
8:53am